Document Detail

Analysis of resveratrol-induced apoptosis in human B-cell chronic leukaemia.
MedLine Citation:
PMID:  12060119     Owner:  NLM     Status:  MEDLINE    
Trans-resveratrol was analysed for its apoptotic and growth inhibitory activity in human B-cell lines derived from chronic B-cell malignancies (WSU-CLL and ESKOL), and in leukaemic lymphocytes from patients with B-cell chronic lymphocytic leukaemia (B-CLL). Resveratrol displayed antiproliferative activity on both B-cell lines, as estimated by the decrease in cell recovery and inhibition of thymidine uptake. Furthermore, resveratrol induced apoptosis in the two cell lines as well as in B-CLL patients' cells, as evidenced by the increase in annexin V binding, caspase activation, DNA fragmentation and decrease of the mitochondrial transmembrane potential DeltaPsim. We previously reported that nitric oxide (NO), endogenously released by an iNO synthase (iNOS) spontaneously expressed in these leukaemic cells, contributed to their resistance towards apoptosis. We show here that resveratrol inhibited both iNOS protein expression and in situ NO release in WSU-CLL, ESKOL and B-CLL patients'cells. In addition, Bcl-2 expression was also inhibited by resveratrol. Thus, downregulation of the two anti-apoptotic proteins iNOS and Bcl-2 can contribute to the apoptotic effects of resveratrol in leukaemic B cells from chronic leukaemia. Our data suggest that this drug is of potential interest for the therapy of B-CLL.
Viviana Roman; Christian Billard; Catherine Kern; Hélène Ferry-Dumazet; Jean-Claude Izard; Ramzi Mohammad; Djavad M Mossalayi; Jean-Pierre Kolb
Related Documents :
17666049 - Early release of arachidonic acid prevents an otherwise immediate formation of toxic le...
10469339 - The inflammatory and cytotoxic effects of a nitric oxide releasing cream on normal skin.
10790579 - Saving the nerve from glaucoma: memantine to caspaces.
23102269 - Quantitative gpcr and ion channel transcriptomics in primary alveolar macrophages and m...
23073139 - Pam(3)csk(4)/tlr2 signaling elicits neutrophil recruitment and restricts invasion of es...
23449239 - The immune response to one-lung-ventilation is not affected by repeated alveolar recrui...
22710659 - The classification of microglial activation phenotypes on neurodegeneration and regener...
15606749 - Weapons of stat destruction. interferon evasion by paramyxovirus v protein.
23435349 - Extracellular acidosis modulates the endocytosis and maturation of macrophages.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  British journal of haematology     Volume:  117     ISSN:  0007-1048     ISO Abbreviation:  Br. J. Haematol.     Publication Date:  2002 Jun 
Date Detail:
Created Date:  2002-06-12     Completed Date:  2002-09-10     Revised Date:  2013-06-03    
Medline Journal Info:
Nlm Unique ID:  0372544     Medline TA:  Br J Haematol     Country:  England    
Other Details:
Languages:  eng     Pagination:  842-51     Citation Subset:  IM    
U.365 INSERM, Institut Curie, 26 rue d'Ulm, 75248 Paris cedex 05, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents, Phytogenic / pharmacology*
B-Lymphocytes / drug effects*,  metabolism,  pathology
Cell Division / drug effects
Gene Expression / drug effects
Genes, bcl-2
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
Nitric Oxide / metabolism
Nitric Oxide Synthase / metabolism
Nitric Oxide Synthase Type II
Stilbenes / pharmacology*
Tumor Cells, Cultured
Reg. No./Substance:
0/Antineoplastic Agents, Phytogenic; 0/Stilbenes; 10102-43-9/Nitric Oxide; EC protein, human; EC Oxide Synthase; EC Oxide Synthase Type II; Q369O8926L/resveratrol
Erratum In:
Br J Haematol. 2002 Dec;119(3):886.

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Marrow matrix metalloproteinases (MMPs) and tissue inhibitors of MMP in acute leukaemia: potential r...
Next Document:  Chromosomal aberrations are shared by malignant plasma cells and a small fraction of circulating CD1...